explore -WSS

explore

author：hotspot 2025-09-28 18:20:46 - browse：4

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Asbestos ban is immediate, but health effects will linger for decades

WSS

Bernie brings in new pharma CEOs to talk drug prices

U.K. officials, researchers try to ease path for bespoke genetic treatments

Pfizer, Moderna say biotech, pharma drug development is a sprint

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

U.K. officials, researchers try to ease path for bespoke genetic treatments

Erich Jarvis studies song birds to learn about human stuttering

focus

explore

focus

Medical records are filled with copy

Yancopoulos of Regeneron works to expand Dupixent success

Bright Health sells Medicare Advantage business to Molina

Adopting new red light myopia treatments may be short

Psychedelics group wrestles with new pharma identity

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Affirmative action in medical school literally saved lives

The CDC's new social media misinformation war

Moonlake's readout produced a cash windfall. Risks remain

Erich Jarvis studies song birds to learn about human stuttering

leisure time

Why Novartis is going to walk from its acquisition of MorphoSys

CRISPR technology availability, affordability needs to be expanded

Top private equity targets in 2023: cardiology, clinical trials, lasers

Chinese researcher claims birth of first gene

A single Democrat is willing to weaken Medicare negotiation power

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

leisure time

hotspot

hotspot

explore